NCT03620032 2023-12-06
DIPG
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
Clinical Trials
3 trialsNCT04833205 2021-04-20
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
Hebei Medical University
Phase 2 Unknown
NCT03388372 2018-01-03
Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma
Biotech Pharmaceutical Co., Ltd.
Phase 2 Completed